Patients Eagerly Awaited a Generic Drug. Then They Saw the Price. - The New York Times
Teva sues FDA over bid to block approval of generic Copaxone
EU antitrust authorities launch probe of Teva over Copaxone drug | The Times of Israel
After Multiple Failures, Teva Returns Laquinimod Rights to Active Biotech | BioSpace
Teva to Pay $85 Million Settlement in Oklahoma Opioid Case | Time
Biogen sues Teva over MS generic
Teva Pharmaceuticals - Wikipedia
EC Investigating Teva for Competing MS Drug
Teva drops laquinimod for most common form of MS after failed trial - PMLiVE
Two decades of glatiramer acetate: From initial discovery to the current development of generics - Journal of the Neurological Sciences
Teva Pharmaceuticals - Wikipedia
U.S. sues Teva over alleged kickbacks for multiple sclerosis drug | Reuters
Teva faces US government lawsuit over alleged kickbacks to spur Copaxone use | S&P Global Market Intelligence
Teva's MS Drug Copaxone Looking for Approval in Japan - Jewish Business News
Court refuses injunctions in pharma patent case
Teva Pharma Has Generic 'Tricks' Ahead But Valuation 'A Treat' | Stock News & Stock Market Analysis - IBD
/cloudfront-us-east-2.images.arcpublishing.com/reuters/QWY4KJXSNVKQZH4U3JFZHKO74Q.jpg "Teva must face government's kickback claims over Copaxone - judge | Reuters")
Teva must face government's kickback claims over Copaxone - judge | Reuters
What are the implications of a generic Teva MS drug? Here's what the wags say - STAT
Biogen, Teva benefit as payers ease up on multiple sclerosis meddling: analyst | FiercePharma
Feds accuse Teva of $300M in kickbacks for MS drug - Drug Discovery and Development
Anything but Generic: A map for Selling to Teva Pharmaceuticals
